Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat
Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell, WaiFung Tsang, Olateju Emmanuel, Kathryn M. Pate, Hannes Kettner, Leor Roseman, David Erritzøe, Robin Carhart-Harris
Frontiers in Psychiatry August 6, 2025 DOI: 10.3389/fpsyt.2025.1594307 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 21 |
| Population | Veterans with traumatic brain injuries |
| Intervention | Psilocybin |
| Dose | 1.5g to 3.5g of dried psilocybin mushrooms for the first ceremony, with the option to increase the second dose up to 5g |
| Duration | 6-day retreat, 4-week follow-up |
| Topics | Anxiety Psilocybin |
| Keywords | Mental health Electroencephalography Clinical psychology Sertraline Depression economics Hallucinogen Antidepressant |
| Citations | 3 |
| Data | OPAL OPAL |
| Key findings | Psilocybin retreats were associated with reduced PTSD, depression, and anxiety symptoms and changes in brain connectivity in veterans with TBI. |
Abstract
Introduction: Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological symptoms such as post-traumatic stress disorder (PTSD) and depression. This study investigates the effects of psilocybin administered in retreat settings on veterans with a history of TBI, focusing on mental health outcomes and changes in brain connectivity as measured by EEG.
Methods: A total of 21 participants were recruited through the Heroic Hearts Project, which facilitated access to two six-day psilocybin retreats in Jamaica. Before the retreat, participants underwent three individual and three group coaching sessions to prepare for the experience. During the retreat, two psilocybin ceremonies were held, spaced 48 hours apart. Participants received an initial dose of 1.5g to 3.5g of dried psilocybin mushrooms, with the option to increase the second dose up to 5g. Psilocybin was administered in a tea format, under the supervision of experienced facilitators. Psychological outcomes were assessed using validated questionnaires (PCL-5, PHQ-9, STAI) at baseline (four weeks pre-retreat) and four weeks post-retreat. Electroencephalography (EEG) was used to measure brainwave activity pre- and post-treatment. Paired t-tests were used to analyze changes in psychological scores, while EEG frequency band analysis assessed changes in brain function and connectivity.
Results: Improvements were observed across several mental health measures: PTSD (PCL-5 scores decreased by 50%, p=0.010), depression (PHQ-9 scores decreased by 65%, p<0.001), and anxiety (STAI) scores decreased by 28%, p<0.001). EEG data showed decreased delta and theta power in frontal and temporal regions, indicating potential improvements in cognitive control and emotional processing. Enhanced coherence in alpha and beta bands suggested improved neural communication.
Discussion: The study suggests that psilocybin retreats might provide improvements in psychological well-being and brain connectivity in veterans with TBI. Reduced delta power and normalised theta activity suggest better emotional regulation, while improved coherence in alpha and beta bands may reflect increased cognitive engagement. Further, these preliminary outcomes provide a potential rationale for the design and implementation of larger-scale, controlled studies to validate and expand upon these initial findings.
Comparable studies
Other observational and cohort studies on psilocybin for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Dynamic coupling of whole-brain neuronal and neurotransmitter systems Healthy humans | 2020 | Observational study | |
| Psychedelics not linked to mental health problems or suicidal behavior: A population study Randomly selected United States adults | 2015 | Observational cohort | n = 135,095 |
| Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals Healthy individuals | 2022 | Observational cohort | n = 39 |
| Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees Self-reported healthy volunteers attending psilocybin ceremonies | 2022 | Observational cohort | n = 52 |
| Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis Google search queries for psilocybin, psychedelic therapy, cannabis, cocaine,... | 2023 | Observational trend analysis |
Citations in the library
Cited by 5
- Quantifying psilocybin exposure in a natural product–based retreat setting: An observational field method for dose measurement Psychedelics July 18, 2026
- Effects of an international ceremonial ayahuasca retreat on the diversity and community composition of the human gut microbiome: A preliminary observational single-arm pre-post study Brain Behavior and Immunity Integrative July 1, 2026
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
- Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series Frontiers in Pharmacology June 3, 2026
- The Emerging Neurobiology of Psychedelics: Critical Periods, Metaplasticity, and Extracellular Matrix Remodeling. Annual Review of Neuroscience July 1, 2026
Cites 36
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up Journal of Psychopharmacology February 1, 2022
- Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports February 10, 2020
and 31 more in the library